

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
1	16/EM/0512	215840	TRILOGY	06/01/2017	04/04/2017	28/02/2017	05/04/2017	20/04/2017	21/04/2017	02/05/2017	Benchmark met
2	16/NW/0517	188554	Myeloma XII (ACCoRd trial) Version 1.0	01/11/2016	09/05/2017	27/10/2016	13/07/2017	22/05/2017	22/05/2017	25/01/2018	Neither
3	16/NE/0142	202233	CANC 5578 (B9991010)	05/05/2017	05/05/2017	01/11/2016	31/08/2017	23/05/2017	25/05/2017	25/09/2017	NHS Provider
4	17/SC/0055	219468	AIN457 Paed	18/05/2017	22/05/2017	21/03/2017	19/06/2017	23/05/2017	30/05/2017	01/06/2017	Benchmark met
5	17/EE/0079	220827	CL010_168	25/01/2017	20/04/2017	06/04/2017	09/05/2017	22/06/2017	30/06/2017	07/02/2018	Neither
6	16/YH/0157	204585	PLATO - Personalising Anal cancer radioTherapy dOse	08/06/2017	08/06/2017	20/07/2016	10/05/2017	23/06/2017	26/06/2017	04/07/2017	Benchmark met
7	17/LO/0035	218519	ACTiF - RCT and parallel process evaluation (WP 3.2 and 3.3)	06/01/2017	16/05/2017	03/04/2017	12/05/2017	20/07/2017	18/09/2017	19/10/2017	Sponsor
8	17/SW/0127	225959	Flight-A multicentre randomised trial of First Line treatment pathways for newly diagnosed Immune Thrombocytopenia: Standard steroid treatment versus combined steroid and mycophenolate	15/05/2017	19/06/2017	03/07/2017	13/07/2017	20/07/2017	26/10/2017	06/11/2017	Sponsor
9	16/LO/1222	191705	ATLANTIS Trial	17/10/2016	12/05/2017	05/05/2017	21/06/2017	17/07/2017	11/08/2017		Neither
10	17/EM/0063	213979	Gilteritinib as Maintenance After Induction/Consolidation in CR1 AML (Astellas AML Maintenance Study)	12/01/2016	19/04/2017	27/04/2017	22/05/2017	31/08/2017	08/09/2017		Neither
11	16/NE/0325	199217	ECUSTEC	16/09/2016	05/06/2017	30/05/2017	13/07/2017	14/07/2017	02/08/2017	21/09/2017	Neither
12	17/NE/0117	222778	Osteogenesis Imperfecta 3082/0003 Mereo BioPharma	20/01/2017	22/06/2017	25/08/2017	20/07/2017	18/07/2017	25/09/2017		Sponsor
13	17/SC/0142	215503	The 65 Trial (v1.0)	20/03/2017	07/07/2017	24/04/2017	11/07/2017	17/07/2017	31/07/2017	08/09/2017	Benchmark met
14	16/YH/0452	130824	VINILO	16/08/2016	04/05/2017	09/12/2016	27/07/2017	09/05/2017	10/05/2017	03/07/2017	Benchmark met
15	17/NW/0022	219189	Post-Authorization Study of HyQvia in Pediatric PIDD subjects	09/01/2017	27/06/2017	06/03/2017	06/07/2017	27/07/2017	08/08/2017	14/08/2017	Benchmark met
16	17/SC/0083	218035	CV185362 Pediatric Anticoagulation for Prevention of Thromboembolism	03/02/2017	10/04/2017	07/07/2017	07/07/2017	27/07/2017	23/08/2017	20/09/2017	Sponsor
17	17/SC/0039	220282	MAGPIE	03/05/2017	05/07/2017	18/04/2017	07/07/2017	11/07/2017	07/08/2017	14/08/2017	Benchmark met
18	16/LO/2141	200571	Biomede	06/06/2017	07/07/2017	06/04/2017	10/08/2017	07/07/2017	12/07/2017	27/07/2017	Benchmark met
19	16/NW/0629	211995	CF START	15/08/2017	08/09/2017	22/09/2016	02/08/2017	05/10/2017	14/12/2017	09/01/2018	Sponsor
20	17/NW/0223	219119	Evaluation of PKU explore	08/08/2017	07/09/2017	22/04/2017	24/11/2017	14/09/2017	29/09/2017	24/10/2017	Benchmark met
21	16/LO/1457	199790	HEPA 5188	01/02/2017	16/05/2017	12/10/2016	31/08/2017	19/09/2017	21/09/2017	10/10/2017	NHS Provider
22	16/EM/0194	194984	DERM 5311	24/08/2016	06/06/2017	24/06/2016	18/10/2017	12/06/2017	03/07/2017	03/08/2017	Benchmark met
23	17/EM/0152	216307	Post-transplant Gilteritinib maintenance in acute myeloid leukaemia	19/10/2016	15/09/2017	21/07/2017	12/01/2018	15/12/2017	08/01/2018	17/01/2018	Sponsor
24	17/LO/0038	182633	UK P3BEP Trial	22/05/2017	22/09/2017	06/04/2017	05/10/2017	13/10/2017	18/10/2017		Neither
25	16/WS/0089	197457	PARADIGM-2	09/06/2017	27/07/2017	16/12/2016	06/10/2017	15/08/2017	31/08/2017	11/09/2017	Benchmark met
26	17/LO/0023	215490	MUK nine b: OPTIMUM	12/01/2017	30/08/2017	30/03/2017	06/12/2017	12/01/2018	17/01/2018		Both
27	17/LO/0249	220398	CO39385: Study of Atezolizumab + Enzalutamide vs Enzalutamide in mCRPC	16/06/2017	13/07/2017	28/04/2017	05/10/2017	22/08/2017	16/11/2017		Both

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
28	17/SC/0228	219158	Javelin Head and Neck	16/12/2016	02/08/2017	24/07/2017	28/10/2017	05/12/2017	17/01/2018	23/03/2018	Both
29	16/WS/0165	190574	ADSCaN.	19/07/2017	02/08/2017	13/02/2017	29/11/2017	28/09/2017	22/12/2017	22/03/2018	Both
30	17/WA/0087	222840	The Caravaggio Study	26/06/2017	14/09/2017	06/07/2017	10/11/2017	10/10/2017	12/10/2017	10/11/2017	Benchmark met
31	17/LO/1174	229691	Phase 2 of Filgotinib in patients with active non-infectious uveitis	19/06/2017	27/09/2017	22/08/2017	21/12/2017	30/11/2017	04/12/2017		Neither
32	17/WM/0110	212527	PHITT	28/06/2017	12/10/2017	28/04/2017	22/11/2017	29/11/2017	29/11/2017	30/11/2017	Benchmark met
33	16/SC/0271	187103	plasmaMATCH	16/06/2017	16/10/2017	21/09/2016	15/01/2018	15/11/2017	24/11/2017	27/11/2017	Benchmark met
34	16/LO/0680	186642	SMILE (PENTA 17)	10/11/2016	09/11/2017	28/07/2016	24/01/2018	05/01/2018	06/03/2018		Sponsor
35	17/LO/1656	229212	IMspire 170	18/08/2017	09/11/2017	14/11/2017	22/11/2017	05/12/2017	11/12/2017	12/01/2018	Benchmark met
36	17/LO/1865	232414	IKEMA (EFC15246) - Combination therapy with isatuximab in patients with multiple myeloma	11/04/2017	21/02/2018	13/12/2017					70 days Not yet reached
37	17/SW/0174	228278	A Phase 2 Clinical Trial in Patients with AML version amend 4	11/09/2017	26/02/2018	20/02/2018	19/01/2018	19/03/2018	21/03/2018		70 days Not yet reached
38	16/NS/0106	212541	RAACENO	11/10/2017	11/10/2017	04/04/2017	22/02/2018	24/11/2017	13/12/2017	21/02/2018	Neither
39	17/LO/0334	214459	FLO-ELA	16/11/2017	24/11/2017	29/03/2017	21/03/2018	08/02/2018	05/03/2018	15/03/2018	Sponsor
40	17/EM/0301	209448	The SANDWICH Trial	04/08/2017	05/12/2017	29/09/2017	19/01/2018	14/12/2017	31/01/2018	06/02/2018	Benchmark met
41	15/WA/0391	180498	MONOCLE	23/01/2017	04/07/2017	16/11/2016	27/02/2018	07/07/2017	07/07/2017	11/07/2017	Benchmark met
42	15/EM/0543	176792	Phase 3 Blinatumomab in Paediatric Subjects With Bprecursor ALL	17/03/2017	21/08/2017	14/02/2017	13/04/2018	22/02/2018			Sponsor
43	17/YH/0392	230501	BI 1467335 in patients with diabetic retinopathy.	04/08/2017	13/12/2017	26/01/2017	09/03/2018	23/01/2018	19/02/2018		Sponsor
44	17/LO/1943	233068	Phase III study of inclisiran sodium in subjects with HeFH	09/10/2017	02/01/2018	10/01/2018	24/01/2018	25/01/2018			Sponsor
45	17/EE/0474	229785	AdAPT: Adenovirus after Allogeneic Paediatric Transplantation	24/11/2017	26/01/2018	05/01/2018	13/03/2018				70 days Not yet reached
46	16/LO/1502	178292	CTC-STOP	25/01/2018	26/01/2018	07/10/2016					70 days Not yet reached
47	16/ES/0110	207747	TOPaZ study	13/01/2017	16/02/2018	12/01/2017					70 days Not yet reached
48	18/SW/0002	233850	CONSTANT	12/10/2017	20/02/2018	20/02/2018	22/02/2018	22/02/2018	05/03/2018	21/03/2018	Benchmark met
49	17/SS/0082	222441	SoSTART	08/02/2018	27/02/2018	05/10/2017	28/03/2018				70 days Not yet reached
50	17/EE/0437	233853	AQUILA (54767414SMM3001)	09/08/2017	28/02/2018	10/01/2018	15/03/2018				70 days Not yet reached
51	16/LO/1495	207629	SPACE	05/12/2017	09/03/2018	12/06/2017	11/04/2018	12/03/2018			70 days Not yet reached
52	17/SC/0345	225047	A Single-dose Pharmacokinetics Study of MK-7655A in Pediatric Subjects	14/07/2017	15/03/2018	05/10/2017	16/05/2017				70 days Not yet reached

Performance Against Initiation Benchmark

Count	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Date of First Patient Recruited	Reasons for delay correspond to:
53	16/EE/0446	214004	Niraparib in men with mCRPC and DNA repair anomalies	05/02/2018	16/03/2018	04/01/2017	12/06/2017	16/03/2018			70 days Not yet reached
54	17/SW/0201	180937	MiBRVO	01/01/2015	16/03/2018		13/06/2017				70 days Not yet reached
55	17/SW/0202	180940	MiCRVO	01/01/2015	16/03/2018	29/01/2018	11/07/2017				70 days Not yet reached
56	17/SC/0471	180934	Oral Minocycline for GA	01/01/2015	23/03/2018	13/03/2018	14/09/2017				70 days Not yet reached
57	18/SC/0055	239091	Be on the TEAM: Teenagers Against Meningitis	18/12/2017	26/03/2018	05/03/2018	19/10/2017	29/03/2018			70 days Not yet reached
58	17/SW/0273	235783	SB11-G31-AMD-Comparison of efficacy&safety of SB11 and Lucentis in AMD	21/07/2017	26/03/2018	22/01/2018	09/01/2018	28/03/2018			70 days Not yet reached
59	18/SC/0015	236685	Adjuvant canakinumab vs placebo in stages IB, II- IIIA resected NSCLC	16/02/2018	27/03/2018	23/02/2018	14/12/2017				70 days Not yet reached
60	16/LO/1979	193891	STATEC	19/07/2016	09/01/2018	20/12/2016	16/01/2018	18/01/2018	23/02/2018	07/03/2018	Benchmark met
61	17/EE/0040	222216	ENCIRCLE Emergency Cerclage in Twins at Imminent Risk of preterm birth	12/01/2018	16/01/2018	02/03/2017	21/02/2018	22/02/2018	26/03/2018		Sponsor
62	17/LO/0108	221119	MASTER DAPT	01/02/2018	13/02/2018	10/04/2017	27/02/2018				70 days Not yet reached
63	18/LO/0205	211278	Thermic-3	28/02/2018	16/03/2018	16/03/2018	16/03/2018				70 days Not yet reached
64	16/LO/2186	188540	IMAT_Neuroblastoma	27/10/2017	16/03/2018	17/01/2017	16/03/2018				70 days Not yet reached
65	17/LO/0731	219463	PIVOTALboost	12/09/2017	21/03/2018	27/07/2017					70 days Not yet reached
66	17/NW/0529	226070	PPAC2: Packing of Perianal Abscess Cavities 2	01/03/2018	27/03/2018	05/12/2017					70 days Not yet reached